c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis

Palbociclib, a CDK4/6 inhibitor, has been granted accelerated approval by US FDA for hormone receptor-positive HER2-negative metastatic breast cancer. To determine potential biomarkers of palbociclib sensitivity to assist in patient selection and clinical development, we investigated the effects of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Wenfei, Zhang, Wenwen, Wang, Xin, Shi, Yaqin, Yang, Fang, Xie, Hui, Zhou, Wenbin, Wang, Shui, Guan, Xiaoxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493901/
https://www.ncbi.nlm.nih.gov/pubmed/32934206
http://dx.doi.org/10.1038/s41419-020-02980-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493901/
https://www.ncbi.nlm.nih.gov/pubmed/32934206
http://dx.doi.org/10.1038/s41419-020-02980-2

Ejemplares similares